SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2021
2020
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
6/16/2021
24-month follow-up of Phase IIb Diamyd
®
clinical trial indicates continued similar progression after 15 months
6/2/2021
Diamyd Medical elected to present Diamyd
®
meta-analysis results at the EASD diabetes conference
5/21/2021
Diamyd
®
Phase IIb trial results published in Diabetes Care
4/29/2021
The 24-month follow-up of DIAGNODE-2 with the diabetes vaccine Diamyd
®
will be presented in early July
4/21/2021
Diamyd Medical to present at Precision Medicine conference
4/20/2021
Diamyd Medical brings Dr Karin Hehenberger to its Board
4/15/2021
Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd
®
4/9/2021
Fully recruited clinical trial in LADA with Diamyd
®
3/29/2021
Diamyd Medical to present at upcoming scientific conferences
3/25/2021
Diamyd Medical carries out a directed share issue and raises proceeds of SEK 60 million
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research